CN103153312B - 用于预防性治疗和治疗性治疗疱疹感染的吡罗昔康 - Google Patents
用于预防性治疗和治疗性治疗疱疹感染的吡罗昔康 Download PDFInfo
- Publication number
- CN103153312B CN103153312B CN201180021384.XA CN201180021384A CN103153312B CN 103153312 B CN103153312 B CN 103153312B CN 201180021384 A CN201180021384 A CN 201180021384A CN 103153312 B CN103153312 B CN 103153312B
- Authority
- CN
- China
- Prior art keywords
- piroxicam
- reagent
- herpes
- purposes
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002702 piroxicam Drugs 0.000 title claims abstract description 15
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 206010019973 Herpes virus infection Diseases 0.000 title description 6
- 230000009385 viral infection Effects 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 208000004898 Herpes Labialis Diseases 0.000 claims description 4
- 206010067152 Oral herpes Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 208000007514 Herpes zoster Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229960001259 diclofenac Drugs 0.000 description 5
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 229960004752 ketorolac Drugs 0.000 description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及用于预防性和治疗性治疗病毒感染的试剂，所述病毒感染特别是来自疱疹病毒家族的那些，所述试剂包含载体物质中的吡罗昔康。
Description
本发明涉及用于预防性和治疗性治疗病毒感染的试剂，所述病毒感染大致是疱疹感染，特别是单纯疱疹。
长期以来，对人和动物中的病毒感染的治疗一直是种挑战，原因是活性成分的数量受到限制。对于疱疹科的病毒也同样如此。
疱疹病毒家族(疱疹病毒)包括具有双链DNA的大量病毒。很常见的是HSV1和HSV2型的单纯疱疹病毒以及水痘-带状疱疹-病毒VZV。它们都导致疼痛的感染，其表现为体表炎症。疱疹病毒在人体中长时间存活，从而其总是导致疾病重复爆发，带有部分加重的疾病现象。
单纯疱疹感染主要在口唇区出现，并且表现为黏膜和嘴唇的起疱和损伤。水痘-带状疱疹-感染在儿童时期大多表现为水痘形式，而在成年时期大多表现为带状疱疹。后者导致脊神经区域中，大致在腰部、胸部以及脸部区域中的疼痛性疹。带状疱疹感染伴随发热、厌食、四肢疼痛和起疹区域的疼痛。
针对疱疹病毒已开发了一系列试剂，但是所述试剂基本上都仅适于缓和症状，但是对疾病进程仅发挥轻微影响。大多数情况下，它们仅轻微缩短疾病持续时间。大量使用的活性成分是阿昔洛韦。
原则上目前需要试剂，用其可以有效抑制病毒感染特别是疱疹感染。
EP 1457202A2中描述了用所谓非类固醇抗炎剂(NSAIDs)来治疗疱疹感染的用途。尽管在所述申请中列举了大量NSAIDs，仅描述了所述各类中的两种代表双氯芬酸和酮咯酸的效力，并且仅双氯芬酸有可靠数据进行证明。根据所述描述，双氯芬酸在局部应用中适用于减轻疾病进程；平均5天后实现对损伤的治疗。这显然是对持续10天的正常感染持续时间的缩短，但是对于患者来说人不够令人满意。
现在令人惊讶地发现，属于NSAIDs类的活性成分吡罗昔康适于预防性和治疗性地治疗病毒感染。吡罗昔康对一系列病毒引起的疾病比如说Η1Ν1型流感病毒造成的流感具有阳性影响，并且特别适于预防以及快速治疗疱疹感染，比如HSV1和HSV2型的那些，特别是唇疱疹。吡罗昔康，4-羟基-2-甲基-N-吡啶-2-基-2H-1,2-苯并噻嗪-3-甲酰胺-1,1-二氧化碳，是COX-抑制剂并且可以用作抗风湿药。
相应地，本发明涉及前述领域的试剂，其包含在适当载体物质中的吡罗昔康。
根据本发明的试剂包含吡罗昔康，其量优选为0.1至10重量%，优选0.1至5，特别优选0.5至5重量%。它可以进行局部、口服和胃肠道给药。
优选地，在口唇区感染（通常称为唇疱疹）的情况下，使用根据本发明的试剂。在此，其涉及单纯疱疹-病毒HSV1和HSV2的感染。同样地，还产生针对带状疱疹VZV的效力。在全部这些感染中，都形成体表疼痛性疹。
本发明试剂通常局部给药，特别是以霜剂、软膏剂、凝胶或酊剂形式局部给药。它们包含常用的载体物质，也即在医药领域惯用的用于霜剂、软膏剂、凝胶和酊剂的配制剂的常用载体物质。
此外，同样可以以片剂形式、作为粉末、输注液或注射液给药。
一般来说，将试剂应用于患者1至5次，每天1至2次。对于大多数患者来说，一次应用即可称为成功。
据频繁罹患单纯疱疹感染的众多患者报告在紧张情况下的预防性应用可以预防起疹，所述紧张情况通常导致形成疱疹。
试验报告1
借助市场上的活性成分含量为0.5重量%的吡罗昔康凝胶，在42名受试者上测试根据本发明的试剂，得到下文列出的结果：
在42名受试者中，26名使用试剂1次，而16名受试者使用试剂达5次。
在42名受试者中，15名在一天之内就确认了改善(包括预防疾病爆发)，21名在1至3天确认了改善，而2名在4至10天确认了改善。41名受试者认为相容性良好，而1名受试者认为一般。1名受试者指出，本发明试剂没有帮助。
吡罗昔康的效力本身即是令人惊讶的。该活性成分原先设计为抗风湿药，化学正确地称为4-羟基-2-甲基-N(2-吡啶基)-2H-1,2-苯并噻嗪-3-甲酰胺-1,1-二氧化碳，其在很大程度上作为止痛剂给药。它在化学上完全不同于上文描述的NSAIDs双氯芬酸和酮咯酸，从而基于其化学结构无法推演出对疱疹病毒且特别是对单纯疱疹/唇疱疹的抗病毒效果。与双氯芬酸和酮咯酸相反，其适于预防起疹。
试验报告2
在筛选测试中，根据标准方法，在感染HSV1型疱疹病毒的培养物上测试具有0.4%活性成分含量的包含吡罗昔康的凝胶。最初log CD50-值为2.50，最初病毒滴度为7.00。在1、5和60分钟作用时间之后，病毒滴度(log10 TCID50/ml)为小于2.50，其对应于大于99.99%的病毒数减少。
Claims (7)
1.吡罗昔康用于制备预防性和治疗性治疗单纯疱疹病毒引起的病毒感染的抗病毒试剂的用途，其中所述吡罗昔康被包含在载体物质中，并且其中所述试剂具有抵抗单纯疱疹病毒的抗病毒活性。
2.根据权利要求1的用途，其特征在于所述试剂中吡罗昔康的含量为0.1至10重量％。
3.根据权利要求2的用途，其特征在于所述试剂中吡罗昔康的含量为1至5重量％。
4.根据权利要求1-3中任一项的用途，其中所述病毒感染是唇疱疹的感染。
5.根据权利要求1-3中任一项的用途，其中所述试剂为用于局部给药的试剂。
6.根据权利要求5的用途，其中所述试剂为霜剂、软膏剂、酊剂或凝胶的形式。
7.根据权利要求1至3中任一项的用途，其中所述试剂用于输注或者注射。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010014290.5 | 2010-04-08 | ||
| DE102010014290A DE102010014290A1 (de) | 2010-04-08 | 2010-04-08 | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
| PCT/EP2011/001704 WO2011124366A1 (de) | 2010-04-08 | 2011-04-06 | Piroxicam zur prophylaktischen und therapeutischen behandlung von herpes - infektionen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103153312A CN103153312A (zh) | 2013-06-12 |
| CN103153312B true CN103153312B (zh) | 2015-07-22 |
Family
ID=43970974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180021384.XA Active CN103153312B (zh) | 2010-04-08 | 2011-04-06 | 用于预防性治疗和治疗性治疗疱疹感染的吡罗昔康 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130190301A1 (zh) |
| EP (1) | EP2374461B1 (zh) |
| JP (1) | JP6158077B6 (zh) |
| CN (1) | CN103153312B (zh) |
| CA (1) | CA2795334C (zh) |
| DE (1) | DE102010014290A1 (zh) |
| DK (1) | DK2374461T3 (zh) |
| ES (1) | ES2612584T3 (zh) |
| PL (1) | PL2374461T3 (zh) |
| RU (1) | RU2555765C2 (zh) |
| WO (1) | WO2011124366A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
| DE102013003756A1 (de) | 2013-03-06 | 2014-09-11 | DeaValorum UG (haftungsbeschränkt) | Piroxicam zur prophylaktischen und therapeutischen Behandlung von CMV-Infektionen |
| DE102013014787A1 (de) | 2013-09-09 | 2015-03-12 | Dauphine UG (haftungsbeschränkt) | Mittel zur prophylaktischen und therapeutischen Behandlung von EHV-Infektionen |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3437232A1 (de) * | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| IT1216686B (it) * | 1988-04-01 | 1990-03-08 | Chiesi Farma Spa | Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione. |
| IT1230922B (it) * | 1989-06-23 | 1991-11-08 | Giuseppe De Benedittis | Composizione per il trattamento della nevralgia erpetica acuta e della nevralgia post erpetica |
| DE59003020D1 (de) * | 1990-04-26 | 1993-11-11 | Sagitta Arzneimittel Gmbh | Piroxicam enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung. |
| JP3031990B2 (ja) * | 1990-10-19 | 2000-04-10 | 同仁医薬化工株式会社 | 消炎鎮痛クリーム剤組成物 |
| RU2182016C2 (ru) * | 1997-03-20 | 2002-05-10 | Панацея Биотек Лтд. | Спазмолитическая композиция, способ получения спазмолитической композиции |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| US7132452B2 (en) | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
-
2010
- 2010-04-08 DE DE102010014290A patent/DE102010014290A1/de not_active Ceased
-
2011
- 2011-03-04 ES ES11001816.5T patent/ES2612584T3/es active Active
- 2011-03-04 EP EP11001816.5A patent/EP2374461B1/de active Active
- 2011-03-04 PL PL11001816T patent/PL2374461T3/pl unknown
- 2011-03-04 DK DK11001816.5T patent/DK2374461T3/en active
- 2011-04-06 JP JP2013503032A patent/JP6158077B6/ja active Active
- 2011-04-06 RU RU2012147474/15A patent/RU2555765C2/ru active
- 2011-04-06 WO PCT/EP2011/001704 patent/WO2011124366A1/de active Application Filing
- 2011-04-06 US US13/639,357 patent/US20130190301A1/en not_active Abandoned
- 2011-04-06 CN CN201180021384.XA patent/CN103153312B/zh active Active
- 2011-04-06 CA CA2795334A patent/CA2795334C/en active Active
-
2014
- 2014-01-29 US US14/167,676 patent/US20140148447A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Therapeutic effects of feldene piroxicam on herpes zoster;Yamamoto M,et al.;《Acta Dermatologica (kyoto)》;19841231;第79卷(第4期);第315-320页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2612584T3 (es) | 2017-05-17 |
| CA2795334C (en) | 2015-06-09 |
| RU2012147474A (ru) | 2014-05-20 |
| JP2013523789A (ja) | 2013-06-17 |
| US20130190301A1 (en) | 2013-07-25 |
| WO2011124366A1 (de) | 2011-10-13 |
| JP6158077B6 (ja) | 2018-08-29 |
| DK2374461T3 (en) | 2017-02-06 |
| DE102010014290A1 (de) | 2011-10-13 |
| CA2795334A1 (en) | 2011-10-13 |
| EP2374461B1 (de) | 2016-10-26 |
| JP6158077B2 (ja) | 2017-07-05 |
| US20140148447A1 (en) | 2014-05-29 |
| CN103153312A (zh) | 2013-06-12 |
| EP2374461A1 (de) | 2011-10-12 |
| RU2555765C2 (ru) | 2015-07-10 |
| PL2374461T3 (pl) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9387227B2 (en) | Method for treatment of sores and lesions of the skin | |
| SK3072003A3 (en) | Methods for delaying recurrence of herpes virus symptoms | |
| CN106668832B (zh) | 一种多肽在制备治疗肠道病毒感染药物的应用 | |
| EA037085B1 (ru) | Композиция для устранения заложенности носа, обладающая противовирусным действием | |
| CN112007163B (zh) | 用于治疗非洲猪瘟的药物组合物及其用途 | |
| US20090220440A1 (en) | Spray Composition for Topical Use for Treating and/or Preventing Herpes Simplex Labial Infections | |
| CN103153312B (zh) | 用于预防性治疗和治疗性治疗疱疹感染的吡罗昔康 | |
| CN104288727B (zh) | 一种小儿风寒感冒保健专用的中药复方制剂 | |
| ES2436037T3 (es) | Spray nasal o gotas nasales para el tratamiento del resfriado común | |
| CN103784336B (zh) | 一种含牛乳铁蛋白的牙膏 | |
| MXPA06013050A (es) | Composiciones a base de compuestos inmunoreguladores para el tratamiento o prevencion de infecciones virales respiratorias. | |
| WO2022019742A1 (es) | Paquete farmaceutico para prevención y/o tratamiento de enfermedad por covid-19 y uso del mismo | |
| RU2009128724A (ru) | Применение композиции, состоящей из низкомолекулярных фрагментов пептидогликана грам-отрицательных бактерий, для лечения и профилактики заболеваний человека | |
| Romero Maroto et al. | Management of oral lesions in Lesch-Nyham syndrome | |
| ES2928418T3 (es) | Uso de vidofludimus para el tratamiento de infecciones por coronavirus | |
| WO2017202789A1 (en) | Methods and pharmaceutical compositions for the treatment of filovirus infections | |
| WO2021239165A2 (es) | Péptido para el tratamiento de infecciones originadas por coronavirus | |
| CN105687227A (zh) | 一种口腔粘膜溃疡贴及其制备方法 | |
| Waghchaure et al. | A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT | |
| US20210330706A1 (en) | Children Blood Transfusion and Thymus Hormonal Therapy as Antiviral and Antibacterial Compounds | |
| CN115867288A (zh) | 用于治疗呼吸系统病症的组合物 | |
| WO2012070967A1 (ru) | Ранозаживляющая, противоожоговая, регенерирующая и противовирусная фармацевтическая композиция для местного применения | |
| WO2014140680A8 (en) | Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection | |
| CN104922463A (zh) | 一种治疗小儿风热犯表型水痘的中药膏及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180418 Address after: German Chaanning Bray Hitt Patentee after: Slomianny Jan Address before: Hannover Co-patentee before: Slomianny Jan Patentee before: Meyer Zu Spelbrink Hans Otto |